AB CORPORATE BOND ETF (EYEG)

Company Profile

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The firm's technology platform, PP-001, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). PP-001 has been developed in two clinical-stage ophthalmic formulations: PaniJect, is an intravitreal injection for inflammatory diseases of the eye including posterior uveitis, and PaniDrop, is a nano carrier technology eye drop for ocular surface diseases such as conjunctivitis, dry eye disease and others. The firm is also developing Ocular Bandage Gel (OBG), which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

Company Info

AB CORPORATE BOND ETF

271 Waverley Oaks Rd Ste 108

Waltham MASSACHUSETTS 02452

P: 17817889043

CEO: Franz Obermayr

Employees: 14

Website: http://www.eyegatepharma.com/